Novel Topical Ophthalmic Formulations for Management of Glaucoma

[1]  Robert W. Williams,et al.  Genetic modulation of the iris transillumination defect: a systems genetics analysis using the expanded family of BXD glaucoma strains , 2013, Pigment cell & melanoma research.

[2]  O. Soliman,et al.  Nanoparticle-based topical ophthalmic formulations for sustained celecoxib release. , 2013, Journal of pharmaceutical sciences.

[3]  Hu Yang,et al.  Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. , 2012, ACS nano.

[4]  Hu Yang,et al.  Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[5]  Shin Jung,et al.  Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells , 2011, International journal of nanomedicine.

[6]  A. Mahmoud,et al.  Biodegradable Ocular Inserts for Sustained Delivery of Brimonidine Tartarate: Preparation and In Vitro/In Vivo Evaluation , 2011, AAPS PharmSciTech.

[7]  Robert W. Williams,et al.  Complex interactions of Tyrp1 in the eye , 2011, Molecular vision.

[8]  Prakash Bhagav,et al.  Brimonidine Tartrate–Eudragit Long-Acting Nanoparticles: Formulation, Optimization, In Vitro and In Vivo Evaluation , 2011, AAPS PharmSciTech.

[9]  Singh Kh,et al.  Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane. , 2011 .

[10]  Robert W. Williams,et al.  Genetic dissection of the Gpnmb network in the eye. , 2011, Investigative ophthalmology & visual science.

[11]  Hao Pan,et al.  Design and evaluation of baicalin-containing in situ pH-triggered gelling system for sustained ophthalmic drug delivery. , 2011, International journal of pharmaceutics.

[12]  Prasanta Chowdhury,et al.  Kinetic modeling on drug release from controlled drug delivery systems. , 2010, Acta poloniae pharmaceutica.

[13]  S. Tamizharasi,et al.  Formulation, and Evaluation of Pentoxifylline-Loaded Poly(ε-caprolactone) Microspheres , 2008, Indian journal of pharmaceutical sciences.

[14]  Steven J Siegel,et al.  Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles. , 2008, International journal of pharmaceutics.

[15]  C. Laurencin,et al.  Biodegradable polymers as biomaterials , 2007 .

[16]  V. Bhardwaj,et al.  Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[17]  L. Cantor.  Brimonidine in the treatment of glaucoma and ocular hypertension , 1997, Therapeutics and clinical risk management.

[18]  Weisan Pan,et al.  Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. , 2006, International journal of pharmaceutics.

[19]  M. Garcia‐Fuentes,et al.  New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. , 2005, International journal of pharmaceutics.

[20]  M. Alonso,et al.  The potential of chitosan in ocular drug delivery , 2003, The Journal of pharmacy and pharmacology.

[21]  Sinjan De,et al.  Polymer relationships during preparation of chitosan-alginate and poly-l-lysine-alginate nanospheres. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[22]  L. Cantor,et al.  Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. , 2002, Archives of ophthalmology.

[23]  A. Ludwig,et al.  Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study. , 2002, International journal of pharmaceutics.

[24]  Hong-Ru Lin,et al.  Carbopol/pluronic phase change solutions for ophthalmic drug delivery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[25]  T. Chung,et al.  A method using biodegradable polylactides/polyethylene glycol for drug release with reduced initial burst. , 1999, International journal of pharmaceutics.

[26]  P. Sado,et al.  Ophthalmic drug delivery systems—Recent advances , 1998, Progress in Retinal and Eye Research.

[27]  R. Ritch,et al.  Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment. , 1997 .

[28]  M. Donovan,et al.  Intranasal mucociliary clearance of putative bioadhesive polymer gels , 1996 .

[29]  H. Quigley.  Number of people with glaucoma worldwide. , 1996, The British journal of ophthalmology.

[30]  R. Gurny,et al.  Biodegradable nanoparticles — From sustained release formulations to improved site specific drug delivery , 1996 .

[31]  M. Alonso,et al.  Improvement of Ocular Penetration of Amikacin Sulphate by Association to Poly(butylcyanoacrylate) Nanoparticles , 1991, The Journal of pharmacy and pharmacology.

[32]  M. Hammer,et al.  Viscous corneal protection by sodium hyaluronate, chondroitin sulfate, and methylcellulose. , 1984, Investigative ophthalmology & visual science.

[33]  N. Peppas,et al.  Mechanisms of solute release from porous hydrophilic polymers , 1983 .

[34]  G. Smolin,et al.  Idoxuridine-liposome therapy for herpes simplex keratitis. , 1981, American journal of ophthalmology.

[35]  R. Hatcher.  THE UNITED STATES PHARMACOPEIA. , 1908 .

[36]  U. Shinde,et al.  Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane. , 2011, Die Pharmazie.

[37]  Sudesh Kumar Yadav,et al.  Biodegradable polymeric nanoparticles based drug delivery systems. , 2010, Colloids and surfaces. B, Biointerfaces.

[38]  Francisco Orallo,et al.  Design of New Formulations for Topical Ocular Administration: Polymeric Nanocapsules Containing Metipranolol , 2004, Pharmaceutical Research.

[39]  Mark A Hurst,et al.  Reliability of drop size from multi-dose eye drop bottles: is it cause for concern? , 1999, Eye.

[40]  L A Wheeler,et al.  Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. , 1999, Investigative ophthalmology & visual science.

[41]  C. Goodman.  United States Pharmacopeial Convention , 1988 .

[42]  Jan W. Kuzma,et al.  Basic statistics for the health sciences , 1984 .